IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.69
3.69
Jahresspanne
2.82
5.81
Tagesänderung
-4.16%
Monatliche Änderung
-0.81%
6 month change
-9.56%
Jahresänderung
-0.81%
Vorheriger Schlusskurs
3.8 5
Open
3.6 9
Tief
3.6 9
Hoch
3.6 9
Volumen
59
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 24 February 2009

Full document

Business Context and Reporting Period

This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on February 27, 2009, reporting an event that occurred on February 24, 2009. The filing addresses a notice of delisting received from the NYSE Alternext US LLC regarding the company's failure to meet continued listing standards.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it explicitly states the following financial conditions as the basis for the delisting notice:

  • Stockholder Equity: Less than $6 million.
  • Operating Performance: The company has reported losses from continued operations and net losses in its five most recent fiscal years.

Material Changes

The primary material change is the regulatory status of the company's stock listing. The NYSE Alternext US LLC determined the company is non-compliant with Section 1003(a)(iii) of the Company Guide due to the financial deficiencies noted above. This places the company's continued listing on the exchange at risk.

Outlook, Risks, and Management Commentary

Management Action: The company intends to submit a compliance plan to the Exchange by March 24, 2009. If accepted, the company would have until August 24, 2010, to implement the plan and regain compliance.

Risks and Contingencies: The primary risk is the potential delisting of the company's stock if a satisfactory plan is not submitted or if the company fails to make progress consistent with the plan during the review period. The filing notes that the company has verbally informed the Exchange staff of its intent to submit the plan timely.

Investor Verification Checklist

  • Verify the exact date and content of the compliance plan submission to the NYSE Alternext US LLC (due March 24, 2009).
  • Review the company's most recent audited financial statements to confirm the specific stockholder equity balance and the magnitude of losses over the last five fiscal years.
  • Monitor subsequent filings for the Exchange's acceptance or rejection of the proposed compliance plan.
  • Confirm whether the company has initiated any capital raising activities or strategic transactions to address the equity deficiency.